| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 27/12/2024 | 22:13 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IVVD | Invivyd Inc |
| 14/11/2024 | 15:16 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:IVVD | Invivyd Inc |
| 14/11/2024 | 13:24 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:IVVD | Invivyd Inc |
| 14/11/2024 | 13:05 | GlobeNewswire Inc. | Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights | NASDAQ:IVVD | Invivyd Inc |
| 14/11/2024 | 13:01 | GlobeNewswire Inc. | Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor | NASDAQ:IVVD | Invivyd Inc |
| 12/11/2024 | 14:30 | GlobeNewswire Inc. | Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedR | NASDAQ:IVVD | Invivyd Inc |
| 06/11/2024 | 14:01 | GlobeNewswire Inc. | Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference | NASDAQ:IVVD | Invivyd Inc |
| 06/11/2024 | 13:01 | GlobeNewswire Inc. | Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 | NASDAQ:IVVD | Invivyd Inc |
| 29/10/2024 | 12:03 | GlobeNewswire Inc. | Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability | NASDAQ:IVVD | Invivyd Inc |
| 29/10/2024 | 12:01 | GlobeNewswire Inc. | Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants | NASDAQ:IVVD | Invivyd Inc |
| 16/10/2024 | 13:01 | GlobeNewswire Inc. | Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 | NASDAQ:IVVD | Invivyd Inc |
| 01/10/2024 | 13:01 | GlobeNewswire Inc. | Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data | NASDAQ:IVVD | Invivyd Inc |
| 23/09/2024 | 13:01 | GlobeNewswire Inc. | Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) | NASDAQ:IVVD | Invivyd Inc |
| 12/09/2024 | 13:01 | GlobeNewswire Inc. | Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 | NASDAQ:IVVD | Invivyd Inc |
| 05/09/2024 | 13:01 | GlobeNewswire Inc. | Invivyd to Participate in Upcoming Investor Conferences | NASDAQ:IVVD | Invivyd Inc |
| 04/09/2024 | 13:01 | GlobeNewswire Inc. | Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ | NASDAQ:IVVD | Invivyd Inc |
| 03/09/2024 | 13:01 | GlobeNewswire Inc. | Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest | NASDAQ:IVVD | Invivyd Inc |
| 27/08/2024 | 13:01 | GlobeNewswire Inc. | Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial | NASDAQ:IVVD | Invivyd Inc |
| 14/08/2024 | 14:01 | GlobeNewswire Inc. | Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights | NASDAQ:IVVD | Invivyd Inc |
| 12/08/2024 | 22:01 | GlobeNewswire Inc. | Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights | NASDAQ:IVVD | Invivyd Inc |
| 01/07/2024 | 13:01 | GlobeNewswire Inc. | Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes | NASDAQ:IVVD | Invivyd Inc |
| 14/06/2024 | 13:01 | GlobeNewswire Inc. | Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants | NASDAQ:IVVD | Invivyd Inc |
| 06/06/2024 | 22:59 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IVVD | Invivyd Inc |
| 06/06/2024 | 22:57 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:IVVD | Invivyd Inc |
| 03/06/2024 | 22:01 | GlobeNewswire Inc. | Invivyd to Participate at the Jefferies Global Healthcare Conference | NASDAQ:IVVD | Invivyd Inc |
| 31/05/2024 | 13:05 | GlobeNewswire Inc. | Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial | NASDAQ:IVVD | Invivyd Inc |
| 31/05/2024 | 13:00 | GlobeNewswire Inc. | Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer | NASDAQ:IVVD | Invivyd Inc |
| 29/05/2024 | 13:00 | GlobeNewswire Inc. | Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC) | NASDAQ:IVVD | Invivyd Inc |
| 22/05/2024 | 13:00 | GlobeNewswire Inc. | Invivyd Elects Two New Independent Members to its Board of Directors | NASDAQ:IVVD | Invivyd Inc |
| 16/05/2024 | 22:11 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:IVVD | Invivyd Inc |